Business
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
The anticipated acquisition aligns with GE HealthCare’s precision care strategy with the goal of strengthening the company’s portfolio of offerings in
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nThe anticipated acquisition aligns with GE HealthCare’s precision care strategy with the goal of strengthening the company’s portfolio of offerings in neurological care and its quantitative analysis of brain MRI\n\n\n\nicometrix’s icobrain platform – a comprehensive set of solutions for neurological disease analysis – includes icobrain aria, the first AI Computer-Aided Detection and Diagnosis FDA 510(k) cleared solution for detecting known side effects of amyloid targeting therapies used to treat Alzheimer’s disease\n\n\n\n CHICAGO--(BUSINESS WIRE)--\nGE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer’s disease to meet the growing demand for MRI in personalized treatment planning.\n\n\nTo complement its MR-guided AI-assisted scanning expertise with analysis and reporting in neurological disease assessment, GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems for seamless workflow. icobrain aria includes the first FDA-cleared computer aided detection and diagnosis solution for detecting and quantifying known side effects of amyloid targeting therapies known as Amyloid Related Imaging Abnormalities (ARIA).\n\n\nAccording to Alzheimer’s Association, studies predict that the number of adults living with Alzheimer’s disease will double by 20501. With approvals of new anti-amyloid therapies continuing to increase globally to treat the disease, the demand for more frequent neurological MRI exams also continues to grow. MRI technology is utilized to assess treatment eligibility and monitor potential side effects (brain swelling and microbleeds) of amyloid targeting therapies.\n\n\n“This effort marks a pivotal step in our journey to advance precision care in neurology,” said Roland Rott, President and CEO, Imaging at GE HealthCare. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”\n\n\nThe planned acquisition of icometrix aligns with GE HealthCare’s precision care strategy and is expected to strengthen the company’s clinical decision support applications for timely diagnosis and monitoring thro...